
|Videos|April 5, 2016
Dr. John Mascarenhas on the COMFORT-I/II Studies for Ruxolitinib in Myelofibrosis
Author(s)John Mascarenhas, MD
The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis.
Advertisement
John Mascarenhas, MD, associate professor of medicine, Mount Sinai Hospital, discusses the COMFORT-I and COMFORT-II studies. The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis. In both studies ruxolitinib reduced splenomegaly and improving symptoms, mostly by down-modulating inflammitory cytokine signaling.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
3 Trials Refine Endocrine, HER2-Targeted Therapies at SABCS
2
Exploring Radiation Therapy’s Reach in Prostate Cancer
3
FDA Grants Breakthrough Therapy Designation to Sofi-Cel for R/R T-ALL/LBL
4
BNT113 Garners Fast-Track Designation in PD-L1+ HPV16+ HNSCC
5














































